UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000038515 |
|---|---|
| Receipt number | R000043890 |
| Scientific Title | A verification study for the suppressive effect of the test food on the elevation of postprandial blood glucose: A randomized, placebo-controlled, double-blind, crossover trial |
| Date of disclosure of the study information | 2019/11/07 |
| Last modified on | 2020/04/02 09:12:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A verification study for the suppressive effect of the test food on the elevation of postprandial blood glucose
Acronym
A verification study for the suppressive effect of the test food on the elevation of postprandial blood glucose
Scientific Title
A verification study for the suppressive effect of the test food on the elevation of postprandial blood glucose: A randomized, placebo-controlled, double-blind, crossover trial
Scientific Title:Acronym
A verification study for the suppressive effect of the test food on the elevation of postprandial blood glucose
Region
| Japan |
Condition
Condition
Healthy Japanese subjects
Classification by specialty
| Not applicable | Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To verify the suppressive effect of the test food on the elevation of postprandial blood glucose
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Confirmatory
Trial characteristics_2
Pragmatic
Developmental phase
Not applicable
Assessment
Primary outcomes
The incremental area under the curve (IAUC) of the blood glucose levels
* Measurement points are at before taking the test food, and at 30, 60, 90, 120 minutes after a glucose load.
Key secondary outcomes
1. The levels of maximum (Cmax) blood glucose
2. Blood glucose levels at each measurement point
3. IAUC of the blood insulin levels
4. The levels of maximum (Cmax) blood insulin
5. Blood insulin levels at each measurement point
* Measurement points are at before taking the test food, and at 30, 60, 90, 120 minutes after a glucose load.
Base
Study type
Interventional
Study design
Basic design
Cross-over
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
YES
Dynamic allocation
NO
Institution consideration
Institution is not considered as adjustment factor.
Blocking
NO
Concealment
Central registration
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Period I: Test food
Period II: Placebo
Carbohydrate load: "Sato No Gohan" (150 g; retort cooked rice)
* The intervention sequence is Period I to Period II, and each food is single ingestion.
* Take three tablets of the test food with water at 30 minutes before taking challenge diet (a glucose load)
* Washout period is for one week and more.
Interventions/Control_2
Period I: Placebo
Period II: Test food
Carbohydrate load: "Sato No Gohan" (150 g; retort cooked rice)
* The intervention sequence is Period I to Period II, and each food is single ingestion.
* Take three tablets of the test food with water at 30 minutes before taking challenge diet (a glucose load)
* Washout period is for one week and more.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Healthy Japanese adult subjects
2. Subjects who are judged as eligible to participate in the study by the physician
3. Subjects who are between >= 110 mg/dL and < 126 mg/dL in postprandial blood glucose, or >= 140 mg/dL and < 200 mg/dL in two-hour blood glucose in the 75 g OGTT
Key exclusion criteria
1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Function Claims", or other functional food/beverage in daily
5. Subjects who are currently taking medications (including herbal medicines) and supplement
6. Subjects who are allergic to medicines and/or the test food related products
7. Subjects who are pregnant, lactation, or planning to become pregnant
8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to enroll in anther clinical trial during trial period
9. Subjects who are ineligibility to participate in the study based on the evaluation of the principal physician
Target sample size
34
Research contact person
Name of lead principal investigator
| 1st name | Kazuo |
| Middle name | |
| Last name | YAMAMOTO |
Organization
ORTHOMEDICO Inc.
Division name
CEO
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL
03-3818-0610
kazu@orthomedico.jp
Public contact
Name of contact person
| 1st name | Naoko |
| Middle name | |
| Last name | SUZUKI |
Organization
ORTHOMEDICO Inc.
Division name
R&D Department
Zip code
112-0002
Address
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.
TEL
03-3818-0610
Homepage URL
nao@orthomedico.jp
Sponsor or person
Institute
ORTHOMEDICO Inc.
Institute
Department
Personal name
Funding Source
Organization
Toyo Sugar Refining Co., Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Medical Corporation Seishinkai, Takara Clinic
Name of secondary funder(s)
IRB Contact (For public release)
Organization
the ethical committee of the Takara Clinic, Medical Corporation Seishinkai
Address
9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.
Tel
03-5793-3623
info@takara-clinic.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 11 | Month | 07 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2019 | Year | 10 | Month | 25 | Day |
Date of IRB
| 2019 | Year | 10 | Month | 25 | Day |
Anticipated trial start date
| 2019 | Year | 11 | Month | 08 | Day |
Last follow-up date
| 2020 | Year | 02 | Month | 29 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2019 | Year | 11 | Month | 07 | Day |
Last modified on
| 2020 | Year | 04 | Month | 02 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043890
